Retour à la vidéo
·
ytcs/72rzR4Qo3zo/cheatsheet/z57edhvkf2cspv1vsj0kchhzb187frez
GLP-1 Peptides (Semaglutide) & Osteoarthritis Recovery
Physionic
CheatSheet
Notes
This video breaks down emerging scientific evidence from a 2026 Cell Metabolism study demonstrating that GLP-1 receptor agonists (specifically Semaglutide and Liraglutide) protect and possibly rejuvenate joint cartilage in osteoarthritis through a weight-loss-independent, chondrocyte-reprogramming metabolic pathway.
Points importants
Osteoarthritis progresses via pain, chondrocyte-mediated joint inflammation (PGE2 signaling), and physical joint destruction (cartilage wear and GAG release).
Liraglutide demonstrates direct anti-osteoarthritic actions in animal models by raising the pain threshold, cutting inflammatory PGE2 levels in half, and slowing cartilage degradation.
A 2026 Cell Metabolism study reveals that Semaglutide reprograms chondrocyte energy metabolism via the GLP-1R-AMPK-PFKFB3 pathway, shifting cells from glycolysis to oxidative phosphorylation.
Strict diet-matched mouse experiments isolated the cartilage-restorative benefit of Semaglutide as a weight-loss-independent metabolic mechanism.
A small, 24-week human pilot trial of overweight adults with knee osteoarthritis showed that combining weekly Semaglutide with Hyaluronic Acid (HA) injections resulted in significantly greater pain/function improvement compared to HA alone.
MRI scans of human participants in the Semaglutide group revealed a striking 15% to 17% increase in cartilage thickness after 24 weeks, while the HA-only control group improved by less than 1%.
Major caveats include the unblinded nature of the cartilage imaging, the very small human cohort (n=20), the lack of human control for weight-loss independence, and the focus on metabolic-driven osteoarthritis specifically.